ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals (ACAD) is a clinical-stage biopharmaceutical company focused on disorders of the central nervous system. It is best known for pimavanserin (marketed as Nuplazid in some regions), approved for Parkinson's disease psychosis, and is developing additional indications and programmes in dementia-related psychosis and other neuropsychiatric conditions. Revenue to date has been largely driven by its lead product while the company advances clinical trials and potential label expansions. Investors should be aware that ACADIA’s value is sensitive to binary clinical and regulatory outcomes, patent and exclusivity timelines, and commercial execution. With a market capitalisation around $3.6bn, it sits in the small‑to‑mid cap biotech range and can show higher volatility than large diversified healthcare firms. This summary is for general educational purposes only and not personalised advice; biotech investments carry both upside potential and significant downside risk, and past performance is not indicative of future results.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ACADIA Pharmaceuticals stock with a target price of $28.83, indicating growth potential.
Financial Health
ACADIA Pharmaceuticals is performing well with strong revenue, high profit margins, and solid cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ACAD
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketPharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
CNS-focused pipeline
ACADIA centres on neuropsychiatric and neurodegenerative indications; successful trials could change the investment case, though outcomes are uncertain.
Single-product reliance
Revenue has depended largely on pimavanserin, so commercial performance and patent timelines are key considerations for investors.
Regulatory catalysts ahead
Upcoming trial readouts and regulator decisions can create material share-price moves — both positive and negative — so monitor news and filings closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
ABSCI CORPORATION
ABSCI Corporation is a biotechnology company focused on the discovery and development of targeted immune modulators for the treatment of cancer and other diseases.
